Network Meta-Analysis of Tofacitinib, Biologic Disease-Modifying Antirheumatic Drugs, and Apremilast for the Treatment of Psoriatic Arthritis.

Gladman, Dafna D; Orbai, Ana-Maria; Gomez-Reino, Juan; Chang-Douglass, Stacey; Leoncini, Emanuele; Burton, Hannah E; Kanik, Keith S; Romero, Ana Belen; Cappelleri, Joseph C; Hsu, Ming-Ann

Gladman, Dafna D; Orbai, Ana-Maria; Gomez-Reino, Juan; Chang-Douglass, Stacey; Leoncini, Emanuele; Burton, Hannah E; Kanik, Keith S; Romero, Ana Belen; Cappelleri, Joseph C; Hsu, Ming-Ann.

Afiliação

Gladman DD; Department of Medicine, University of Toronto, Krembil Research Institute, Toronto Western Hospital, Toronto, Ontario, Canada.
Orbai AM; Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Gomez-Reino J; Fundación Ramón Domínguez, Hospital Clinico Universitario, Santiago de Compostela, Spain.
Chang-Douglass S; Decision Resources Group, part of Clarivate, London, United Kingdom.
Leoncini E; Decision Resources Group, part of Clarivate, London, United Kingdom.
Burton HE; Decision Resources Group, part of Clarivate, London, United Kingdom.
Kanik KS; Pfizer Inc, Groton, Connecticut.
Romero AB; Pfizer SL, Barcelona, Spain.
Cappelleri JC; Pfizer Inc, Groton, Connecticut.
Hsu MA; Pfizer Inc, Groton, Connecticut.

Curr Ther Res Clin Exp ; 93: 100601, 2020.

Article em En | MEDLINE | ID: mdl-32983284

Palavras-chave

Biologic disease-modifying antirheumatic drug; Network meta-analysis; Psoriatic arthritis; TNFi-IR; TNFi-naïve; Tofacitinib

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Guideline / Prognostic_studies / Qualitative_research / Systematic_reviews Idioma: En Revista: Curr Ther Res Clin Exp Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Canadá

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google